| abemaciclib based treatment | cyclin inhibitor | palbociclib based treatment | ribociclib based treatment |
| abemaciclib plus fulvestrant | dalpiciclib plus fulvestrant | palbociclib plus fulvestrant | ribociclib plus endocrine therapy | ribociclib plus fulvestrant |
la/mBC - HR-positive - 2nd line (L2) 20 | | | | | |
la/mBC - HR positive - L2 - all population 1 | | | | | |
la/mBC - HR positive - L2 - PIK3CA mutant 1 | | | | | |